Patient Characteristics | Â | Limited field | Elective field | p-value |
---|---|---|---|---|
 |  | (n = 11) | (n = 12) |  |
Gender | Female | 9 | 10 | 1.000* |
 | Male | 2 | 2 |  |
Age (years) | < 45 | 0 | 2 | 0.582* |
 | 45 - 64 | 5 | 5 |  |
 | ≥ 65 | 6 | 5 |  |
KPS | 90 | 4 | 6 | 0.680* |
 | 80 | 7 | 6 |  |
Histologic type | Papillary | 11 | 8 | 0.093* |
 | Poorly differentiated | 0 | 4 |  |
Recurrence | Primary tumor | 3 | 5 | 0.667* |
 | Recurrent tumor | 8 | 7 |  |
T stage at diagnosis | T1-2 | 1 | 0 | 0.822* |
 | T3 | 6 | 8 |  |
 | T4 | 4 | 4 |  |
N stage at diagnosis | N0 | 3 | 1 | 0.179* |
 | N1a | 6 | 4 |  |
 | N1b | 2 | 7 |  |
AJCC Stage at diagnosis | I-III | 7 | 6 | 0.680* |
 | IVA | 4 | 6 |  |
T stage at pre-EBRT | T0-2 | 2 | 2 | 1.000* |
 | T3 | 1 | 2 |  |
 | T4 | 8 | 8 |  |
N stage at pre-EBRT | N0 | 2 | 1 | 0.359* |
 | N1a | 3 | 1 |  |
 | N1b | 6 | 10 |  |
AJCC Stage at pre-EBRT | I-III | 1 | 2 | 0.640* |
 | IVA-B | 7 | 8 |  |
 | IVC | 3 | 2 |  |
Tg level (ng/mL) | Median (range) | 13.5 (2.7-449) | 10.7 (0.2-1411) | 0.257†|
 | Mean ± SD | 76.8 ± 137.7 | 232.3 ± 431.7 |  |
 | < 10 | 5 | 6 | 1.000* |
 | ≥ 10 | 6 | 6 |  |
Thyroid surgery | Subtotal thyroidectomy | 2 | 2 | 1.000* |
 | Total thyroidectomy | 9 | 10 |  |
Lymph node surgery | CND | 3 | 3 | 1.000* |
 | CND+Unilateral SND/MRND | 7 | 7 |  |
 | CND+Bilateral SND/MRND | 1 | 2 |  |
Postoperative residuum | R0-1 | 2 | 3 | 1.000* |
 | R2 | 9 | 9 |  |
Radioiodine treatment | No | 1 | 3 | 0.590* |
 | Yes | 10 | 9 |  |
EBRT dose (EQD2, Gy) | Median (range) | 62.5 (62.5-67.7) | 62.5 (60-69) | 0.110†|
 | Mean ± standard deviation | 63.3 ± 1.8 | 65.1 ± 3.1 |  |
EBRT techniques | 3DCRT | 3 | 3 | 1.000* |
 | IMRT | 8 | 9 |  |